HLAG antibody

Catalog No. ABIN94366

Product Details anti-HLAG Antibody

Target: HLAG (HLA Class I Histocompatibility Antigen, alpha Chain G (HLAG))

Reactivity: Human

Host: Mouse

Clonality: Monoclonal

Conjugate: This HLAG antibody is un-conjugated

Application: Western Blotting (WB), Immunohistochemistry (Frozen Sections) (IHC (fro)), Immunohistochemistry (Paraffin-embedded Sections) (IHC (p))

Specificity: The antibody MEM-G/1 reacts with an extracellular epitope of denaturated HLA-G heavy chain. HLA-G belongs to the MHC Class I molecules (MHC Class Ib, nonclassical) and it is expressed on the surface of trophoblast cells.

Cross-Reactivity (Details): Human

Purification: Purified by protein-A affinity chromatography.

Purity: > 95 % (by SDS-PAGE)

Immunogen: Denatured bacterially expressed recombinant human HLA-G heavy chain.

Clone: MEM-G-1

Isotype: IgG1

Application Details

Application Notes: Immunohistochemistry (paraffin sections): Recommended dilution: 1:60 to 1:100, incubation: 1 h at RT, positive tissue: human placenta - extravillous cytotrophoblast, heat retrieval in 0.01M citrate buffer (4x2 min. in microwave oven).
Western blotting: Recommended dilution 1-2 μg/mL.

Restrictions: For Research Use only

Handling

Concentration: 1 mg/mL

Buffer: Phosphate buffered saline (PBS), pH 7.4, 15 mM sodium azide

Preservative: Sodium azide

Precaution of Use: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Handling Advice: Do not freeze.

Storage: 4 °C

Storage Comment: Store at 2-8°C. Do not freeze.

References for anti-HLAG antibody (ABIN94366)

Jasinski-Bergner, Stehle, Gonschorek, Kalich, Schulz, Huettelmaier, Braun, Seliger: "Identification of 14-3-3? Gene as a Novel miR-152 Target Using a Proteome-based Approach." in: The Journal of biological chemistry, Vol. 289, Issue 45, pp. 31121-35, (2014) (PubMed).

Amiot, Vu, Rauch, LHelgoualch, Chalmel, Gascan, Turlin, Guyader, Samson: "Expression of HLA-G by mast cells is associated with hepatitis C virus-induced liver fibrosis." in: Journal of hepatology, Vol. 60, Issue 2, pp. 245-52, (2014) (PubMed).

Larsen, Bzorek, Pass, Larsen, Nielsen, Svendsen, Lindhard, Hviid: "Human leukocyte antigen-G in the male reproductive system and in seminal plasma." in: Molecular human reproduction, Vol. 17, Issue 12, pp. 727-38, (2011) (PubMed).

Biondi, Ferretti, Lunghi, Medici, Cervellati, Pavan, Vesce, Morano, Adinolfi, Bertoni, Abelli: "cAMP efflux from human trophoblast cell lines: a role for Multidrug Resistance Protein (MRP)1 transporter." in: Molecular human reproduction, (2010) (PubMed).

Gonen-Gross, Achdout, Arnon, Gazit, Stern, Horejsí, Goldman-Wohl, Yagel, Mandelboim: "The CD85J/leukocyte inhibitory receptor-1 distinguishes between conformed and beta 2-microglobulin-free HLA-G molecules." in: Journal of immunology (Baltimore, Md. : 1950), Vol. 175, Issue 8, pp. 4866-74, (2005) (PubMed).

Shih, Kurman: "p63 expression is useful in the distinction of epithelioid trophoblastic and placental site trophoblastic tumors by profiling trophoblastic subpopulations." in: The American journal of surgical pathology, Vol. 28, Issue 9, pp. 1177-83, (2004) (PubMed).

Boyson, Erskine, Whitman, Chiu, Lau, Koopman, Valter, Angelisova, Horejsi, Strominger: "Disulfide bond-mediated dimerization of HLA-G on the cell surface." in: Proceedings of the National Academy of Sciences of the United States of America, Vol. 99, Issue 25, pp. 16180-5, (2002) (PubMed).

Hurks, Valter, Wilson, Hilgert, van den Elsen, Jager: "Uveal melanoma: no expression of HLA-G." in: Investigative ophthalmology & visual science, Vol. 42, Issue 13, pp. 3081-4, (2001) (PubMed).

Frumento, Franchello, Palmisano, Nicotra, Giacomini, Loke, Geraghty, Maio, Manzo, Natali, Ferrara: "Melanomas and melanoma cell lines do not express HLA-G, and the expression cannot be induced by gammaIFN treatment." in: Tissue antigens, Vol. 56, Issue 1, pp. 30-7, (2000) (PubMed).

Fournel, Huc, Aguerre-Girr, Solier, Legros, Praud-Brethenou, Moussa, Chaouat, Berrebi, Bensussan, Lenfant, Le Bouteiller: "Comparative reactivity of different HLA-G monoclonal antibodies to soluble HLA-G molecules." in: Tissue antigens, Vol. 55, Issue 6, pp. 510-8, (2000) (PubMed).

Target Details for HLAG

Target: HLAG (HLA Class I Histocompatibility Antigen, alpha Chain G (HLAG))

Alternative Name: HLA-G (HLAG Products)

Synonyms: MHC-G antibody, B-F antibody, B-F-S04 antibody, B-F-S05 antibody, B-F-S06 antibody, B-F-S07 antibody, B-FI antibody, B-FIV antibody, BF2 antibody, BFa2 antibody, BFw-03 antibody, BFw-05 antibody, BFz-01 antibody, major histocompatibility complex, class I, G antibody, MHC BF1 class I antibody, HLA-G antibody, BF1 antibody

Background: Major histocompatibility complex, class I, G,Human leukocyte antigen G (HLA-G), belonging to MHC class I glycoproteins, plays important roles in both physiological and pathological immunotolerance. It gives an inhibitory signal to cytotoxic T cells, NK cells, monocytes, and some other immune cells. It also induces regulatory T cells and anti-inflammatory macrophages. HLA-G is important e.g. for maternal tolerance to the fetus, and for immunomodulation in particular adult tissues, such as in cornea, pancreatic islets, thymus and other. On the other hand, it is expressed in many solid and hematologic malignancies, where it contributes to evasion of the immune surveillance. HLA-G expression pattern in cancer is an important prognostic factor regarding a poor clinical outcome. Unlike most other MHC glycoproteins, HLA-G acts as an immune checkpoint molecule rather than as an antigen presenting molecule. It concerns both transmembrane and soluble HLA-G isoforms. Among other, HLA-G can promote Th2 immunological response and downregulate Th1 immunological response. For its benefits regarding allograft tolerance, including embryo implantation, soluble HLA-G (sHLA-G) can be used as a marker of developmental potential of embryos during the process of in vitro fertilization. Similarly, sHLA-G concentrations in maternal serum are decreased in preeclampsia. Transplanted patients with increased sHLA-G serum levels have improved allograft acceptance. On the other hand, increased sHLA-G can also indicate presence of malignant (sometimes also of benign) tumor cells. Another important topic is induction of HLA-G expression (sometimes associated with shedding of HLA-G from the cell surface) by some anti-cancer or anti-viral therapies, which can weaken the therapy effect. Monitoring of HLA-G in patients thus has a wide usage.

Gene ID: 3135

UniProt: P17693

Pathways: Regulation of Leukocyte Mediated Immunity, Positive Regulation of Immune Effector Process, Cancer Immune Checkpoints, Human Leukocyte Antigen (HLA) in Adaptive Immune Response